EU industry: new PV fee plan better, but still much room for improvement
This article was originally published in Scrip
Executive Summary
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes made by the European Commission to its original plans for a pharmacovigilance fee system, but say that there are still major problems with the proposal.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.